Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole pediatric GERD dose-level study
2008-004837-54Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in endoscopic grade, Change from baseline in histologic grade and 2 more. Started Jan 2009; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2008-004837-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004837-54.